• Jashvant Poeran, Jason Babby, Rehana Rasul, Madhu Mazumdar, Stavros G Memtsoudis, and David L Reich.
• From the *Institute for Healthcare Delivery Science, Department of Population Health Science and Policy and Department of Medicine, Icahn School of Medicine at Mount Sinai; †Department of Pharmacy, The Mount Sinai Hospital; ‡Institute for Healthcare Delivery Science, Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai; §Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, Department of Anesthesiology, Hospital for Special Surgery, New York, NY and Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria; and ∥President and Chief Operating Officer of The Mount Sinai Hospital, President of Mount Sinai Queens, and Horace W. Goldsmith Professor of Anesthesiology, New York, NY.
• Reg Anesth Pain Med. 2015 May 1;40(3):284-6.

AbstractThis article aims to discuss and provide insight into the effects of the increased use and price (from $12.43 to $35.40 in 2014) of intravenous acetaminophen, which has rapidly gained acceptance in the field of perioperative medicine. Overall use and characteristics are described for selected surgeries with absolute use particularly high in orthopedic surgeries associated with substantial costs (up to an additional $160,000 per year per hospital for just orthopedic use). The availability of large-scale data on costs and use of intravenous acetaminophen in the United States will greatly benefit the ongoing discussions on its place in current practice.

13 keywords...

hide…